Skip to main content Accessibility help
×
Home

Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice

  • Marina Grishchenko (a1), Richard D. Grieve (a2), Michael J. Sweeting (a3), Daniela De Angelis (a3), Brian J. Thomson (a4), Stephen D. Ryder (a4), William L. Irving (a5) and the Trent HCV Study Group...

Abstract

Objectives: This study assesses whether pegylated interferon and ribavirin is cost-effective compared with no antiviral treatment provided in routine clinical practice, for different patient subgroups.

Methods: The cost-effectiveness analysis (CEA) uses a Markov decision model to estimate the lifetime cost per quality-adjusted life-year (QALY) of antiviral treatment compared with no treatment. The model is populated with data on sustained virological responses, costs, and transition probabilities all taken from a large representative sample of UK cases and centers (Trent HCV database).

Results: The CEA found that pegylated interferon and ribavirin was cost-effective for most patient subgroups. The CEA found that for patients with genotype non-1, the intervention led to cost reductions and gains of at least 0.5 QALYs. For genotype 1 cases with mild or moderate disease, and younger cirrhotic patients (aged 40 or less), costs per QALY remained below £20,000 ($40,000 or €29,000). For genotype 1 cases with cirrhosis aged 50, the mean cost per QALY rose to over £60,000 ($120,000 or €87,000).

Conclusions: The study concludes that, based on cost and effectiveness data collected from routine clinical practice, treatment with pegylated interferon and ribavirin is generally cost-effective. The study shows that there are variations according to patient subgroup and for older (aged 50 or over) genotype 1 patients with cirrhosis, antiviral treatment appears less cost-effective.

Copyright

References

Hide All
1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999;6:3547.
3. Briggs, AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479500.
4. Briggs, AH. Statistical approaches to handling uncertainty in health economic evaluation. Eur J Gastroenterol Hepatol. 2004;16:551561.
5. British Medical Association. British National Formulary (BNF), No. 54. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; September 2007.
6. Bruno, S, Stroffolini, T, Colombo, M et al. , Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology. 2007;45:579587.
7. Castelnuovo, E, Thompson-Coon, J, Pitt, M et al. , The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess. 2006;10:iiiiv, ix–xii, 1–93.
8. Curtis, L. Unit costs of health and social care 2007. Canterbury, UK: PSSRU Personal Social Services Research Unit; 2007.
9. Dalgard, O, Bjøro, K, K, Hellum et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res. 2002;8:4549.
10. Fattovich, G, Giustina, G, Degos, F et al. , Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463472.
11. Freeman, AJ, Dore, GJ, Law, MG et al. , Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34 (pt 1):809816.
12. Fried, MW, Shiffman, ML, Reddy, KR et al. , Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975982.
13. Grieve, R, Roberts, J, Wright, M et al. , Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut. 2006;55:13321338.
14. Hadziyannis, SJ, Sette, H Jr, Morgan, TR et al. , Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346355.
15. Health Protection Agency. Hepatitis C in England: an update. Annual Report. London: Health Protection Agency; 2006.
16. Longworth, L, Bryan, S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 2003;12:10611067.
17. Manns, MP, McHutchison, JG, Gordon, SC et al. , Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958965.
18. Michielsen, PP, Francque, SM, van Dongen, JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27.
19. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf; 2008.
20. National Institute for Health and Clinical Excellence. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. London: NICE; 2004.
21. National Institute for Health and Clinical Excellence. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. London: NICE; 2006.
22. Nishiguchi, S, Shiomi, S, Nakatani, S et al. , Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357:196197.
23. Poynard, T, Mathurin, P, Lai, CL et al. , A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257265.
24. Poynard, T, Yuen, MF, Ratziu, V, Lai, CL. Viral hepatitis C. Lancet. 2003;362:20952100.
25. Ryder, SD, Irving, WL, Jones, DA, Neal, KR, Underwood, JC. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut. 2004;53:451455.
26. Sharma, P, Lok, A. Viral hepatitis and liver transplantation. Semin Liver Dis. 2006;26:285297.
27. Shepherd, J, Jones, J, Hartwell, D et al. , Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess. 2007;11:1224.
28. Siebert, U, Sroczynski, G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care. 2005;21:5565.
29. Sweeting, M, De Angelis, D, Brant, L, Harris, HE, Mann, AG, Ramsay, ME. The burden of hepatitis C in England. J Viral Hepat. 2007;14:570576.
30. Sweeting, MJ, De Angelis, D, Neal, KR et al. , Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol. 2006;59:144152.
31. Tanaka, J, Kumada, H, Ikeda, K et al. , Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol. 2003;70:378386.
32. Thabut, D, Le Calvez, S, Thibault, V et al. , Hepatitis C in 6,865 patients 65 yr or older: A severe and neglected curable disease? Am J Gastroenterol. 2006;101:12601267.
33. Thomson, BJ, Kwong, G, Ratib, S et al. , Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. J Viral Hepat. 2008;15:271278.
34. Wong, JB, McQuillan, GM, McHutchison, JG, Poynard, T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:15621569.
35. Wong, JB, Poynard, T, Ling, MH, Albrecht, JK, Pauker, SG. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol. 2000;95:15241530.
36. Wright, M, Goldin, R, Fabre, A et al. , Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: A cross sectional and longitudinal study. Gut. 2003;52:574579.
37. Wright, M, Grieve, R, Roberts, J, Main, J, Thomas, HC. Health benefits of antiviral therapy for mild chronic hepatitis C: Randomised controlled trial and economic evaluation. Health Technol Assess. 2006;10:1-113, iii.
38. Zeuzem, S, Diago, M, Gane, E et al. , Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004;127:17241732.

Keywords

Related content

Powered by UNSILO
Type Description Title
WORD
Supplementary materials

Grishchenko supplementary material
Figures

 Word (28 KB)
28 KB

Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice

  • Marina Grishchenko (a1), Richard D. Grieve (a2), Michael J. Sweeting (a3), Daniela De Angelis (a3), Brian J. Thomson (a4), Stephen D. Ryder (a4), William L. Irving (a5) and the Trent HCV Study Group...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.